Press Releases

Publication in BMC Medicine demonstrates the combination of SeptiCyte® TRIAGE and SeptiCyte® VIRUS can discriminate between bacterial and viral infections in Emergency Department patients SEATTLE, Sept. 23, 2020 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today new data in collaboration with researchers at the University College of London. …

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of analytical and clinical performance data for SeptiCyte® technology in two posters at the virtual e-ISICEM (International Symposium on Intensive Care and Emergency Medicine), from Sept. 15-18, 2020. The first poster, titled “Clinical Performance of a Rapid Sepsis…

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), of up to $599,549 to…

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe   SEATTLE and BRISBANE, March 26, 2020 – Immunexpress,…

Immunexpress, Pty Ltd & Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced that it has been successfully certified according to ISO 13485:2016 & EN ISO 13485:2016, the international standard for medical device quality management systems. The scope of the certification includes the design and…

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that its Chief Executive Officer, Rolland Carlson, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square. Dr. Carlson will present an overview of the Company’s SeptiCyte™ technology and the…

The patent includes classification techniques using single nucleotide polymorphisms (SNPs) in the ribosomal DNA of sepsis organisms Identification and classification of sepsis organisms leads to improved antibiotic decision-making SEATTLE, Nov. 21, 2019 – Immunexpress, Inc. today announced the U.S. Patent and Trademark Office (USPTO) has granted Patent No. U.S. 10,364,474 B2, which covers single nucleotide…

Immunexpress Announces Closing of Private Funding Round Funding will support the development of SeptiCyte™ RAPID through FDA 510(k) Clearance CE Marking of SeptiCyte™ RAPID anticipated in 1Q2020, FDA Clearance anticipated mid-2020 SEATTLE, Oct. 3, 2019 /PRNewswire/ — Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the closing of a major…

The addition represents the development of a global commercial framework in preparation for SeptiCyte™ RAPID launch Immunexpress, Inc. today announced that Jane Papadaki Markley has joined the company’s Executive Team as Vice President of Market Development and Commercial Operations. “Jane’s impressive ability to incorporate the commercial perspective into development strategies will be influential in our upcoming launch…

Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body’s overwhelming immune response to an infection, which can lead to tissue…